

06/29/00

06/29/00

UTILITY PATENT APPLICATION TRANSMITTAL <small>Form for new nonprovisional applications under 37 CFR 1.53(b)</small>		Attorney Docket No.	2323-139-II	Total Pages	28
First Named Inventor or Application Identifier					
Kirk R. THOMAS					
Express Mail Label No.					

PTO
STN
09/605222
528

APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.	ADDRESS TO: Assistant Commissioner of Patents Box Patent Application Washington, D.C. 20231
1. <input type="checkbox"/> Fee Transmittal Form <small>(Submit an original, and a duplicate for fee processing)</small> 2. <input checked="" type="checkbox"/> Specification Total pages [17] <small>(preferred arrangement set forth below)</small> - Descriptive title of the invention - Cross references to Related Applications - Statement Regarding Fed sponsored R&D - Reference to Microfiche Appendix - Background of the invention - Brief Summary of the Invention - Brief Description of the Drawings - Detailed Description - Claims - Abstract of the Disclosure 3. <input checked="" type="checkbox"/> Drawing(s) (35 USC 113) (Total Sheets) [5] 4. <input type="checkbox"/> Oath or Declaration (Total Pages) [] a. <input type="checkbox"/> Newly executed (original or copy) b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 17 completed) [Note Box 5 below] i <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b) 5. <input type="checkbox"/> Incorporation by Reference (useable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.	6. <input type="checkbox"/> Microfiche Computer Program (Appendix) 7. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. <input checked="" type="checkbox"/> Computer Readable Copy b. <input checked="" type="checkbox"/> Paper Copy (identical to computer copy) one (1) page c. <input checked="" type="checkbox"/> Statement verifying identity of above copies ACCOMPANYING APPLICATION PARTS 8. <input type="checkbox"/> Assignment Papers (cover sheet & documents) 9. <input type="checkbox"/> 37 CFR 3.73(b) Statement <small>(when there is an assignee)</small> 10. <input type="checkbox"/> Power of Attorney 11. <input type="checkbox"/> English Translation Document <small>(if applicable)</small> 12. <input type="checkbox"/> Information Disclosure Statement /PTO 1449 13. <input type="checkbox"/> Copies of IDS Citations 14. <input type="checkbox"/> Preliminary Amendment 15. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <small>(Should be specifically itemized)</small> 16. <input type="checkbox"/> Small Entity Statement(s) <input type="checkbox"/> Statement Filed in prior application, Status still proper and desired 17. <input type="checkbox"/> Certified Copy of Priority Document(s). <small>(if foreign priority is claimed)</small> 18. <input type="checkbox"/> Other:

17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:
☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.:

18. CORRESPONDENCE ADDRESS
☐ Customer Number or Bar Code Label or ☒ Correspondence address below
(Insert Customer No. or Attach bar code label here)

Name	Jeffrey L. Ihnen, Reg. No. 28,957				
Address	Rothwell, Figg, Ernst & Manbeck Suite 701-East, 555 13th Street, N.W.				
City	Washington	State	D.C.	Zip Code	20004
Country	U.S.A.	Telephone	202-783-6040	Fax	202-783-6031

TITLE OF THE INVENTION

SELF-INDUCED DELETION OF DNA

CROSS-REFERENCE TO RELATED APPLICATION

The present application is related to U.S. provisional patent application Serial No. 60/141,267 filed on 30 June 1999, incorporated herein by reference.

This application was made with Government support from National Institutes of Health under Grant Nos. DK49219 and R01 DK51445. The federal government may have certain rights in this invention.

BACKGROUND OF THE INVENTION

The present invention is directed to a method for deleting nucleic acid sequences in a tissue specific manner. The present invention is further directed to a DNA molecule for use in the method.

The publications and other materials used herein to illuminate the background of the invention or provide additional details respecting the practice are incorporated by reference, and for convenience are respectively grouped in the appended List of References.

The paradigm for targeted germ-line modification of a mammalian genome was established twelve years ago (Thomas et al., 1987). An alteration introduced *in vitro* into a cloned gene is transferred by homologous recombination to its chromosomal target in a pluripotent embryo-derived stem (ES) cell. Cells containing the modification are placed in an embryonic environment, allowed to grow, differentiate, and to contribute to the germline of the host organism. Limitations imposed by the transformation and recombination efficiencies of mammalian cells require that the alteration of interest be linked physically to a selectable genetic marker, typically a gene encoding drug resistance under transcriptional control of a constitutive promoter/enhancer element. This operational requirement can have unpredictable consequences *in vivo*, such as misregulation of adjacent genes or the attenuation of expression of the gene of interest (Olson et al, 1996). Thus, the elimination of the marker may be desirable, and for technical reasons is generally performed through use of site-specific recombinase systems such as *Cre/loxP* (Sternberg et al., 1981) or *FLP/FRT* (Broach et al., 1980).

Although the prior art has developed means to remove the marker gene, it is desired to improve upon such means and to provide for better control of the process. These objects are accomplished by the present invention.

SUMMARY OF THE INVENTION

The present invention is directed to a method for deleting nucleic acid sequences in a tissue specific manner. In one embodiment, nucleic acid sequences are specifically deleted in germline tissue. In a second embodiment, nucleic acid sequences are specifically deleted in desired somatic tissue. The present invention is further directed to a DNBA molecule for use in the method.

More specifically, a method is provided by the present invention for the self-excision of nucleic acid sequences in a tissue specific manner. According to this method, a promoter specific to a given tissue, is used to drive expression of the Cre or FLP recombinase. In one embodiment, a gamete-specific promoter, such as a testes-specific promoter or an ovary-specific promoter is used to drive expression of the Cre or FLP recombinase. In this embodiment, foreign DNA, such as a marker gene, linked to *Cre* or *FLP*, survives selection in cultured cells and remains integrated in somatic cells, but is removed along with the *Cre* or *FLP* as both are passed through the germline. In a second embodiment, a somatic tissue specific promoter, such as a muscle specific promoter, is used to drive expression of the Cre or FLP recombinase. In this embodiment, foreign DNA which is integrated in somatic cells is removed along with the *Cre* or *FLP* in the specific tissue under control of the tissue specific promoter. The method can be used in both plants and animals and has many applications as described herein.

More specifically, a DNA acid molecule is provided by the present invention which comprises (a) a recombinase site, (b) a tissue-specific promoter, (c) a recombinase gene, (d) a foreign DNA and (e) a recombinase site. In one embodiment, the tissue specific promoter is a gamete-specific promoter. In a second embodiment, the tissue specific promoter is a somatic tissue specific promoter. The DNA molecule may further comprise a gene which is desired to be incorporated into and expressed in an organism, including a transgenic organism.

A transgenic organism containing the nucleic acid molecule is further provided by the present invention.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows testes-specific self-excision. In Figure 1A, a selectable marker gene Neo', with a constitutive promoter, is transferred by homologous recombination to a specific locus in a mouse ES cell. The Neo' gene is linked to a *Cre* gene that is under transcriptional control of the tACE promoter, and the two genes are flanked with *loxP* sites (P); the entire cassette, ACN, is introduced by gene targeting to a specific locus in a mouse ES cell. In Figure 1B, ES cells,

heterozygous for an allele containing the integrated cassette, are injected into wild-type mouse blastocysts and the blastocysts allowed to develop; the resulting animals are chimeric for wild-type (host-derived) cells (white) and ES-derived cells (black). As shown in Figure 1C, male chimeric animals will transmit through their sperm one of two alleles of the locus of interest: wild-type (white) or mutant (gray); after self-excision has occurred, the mutant allele will be marked only by a *loxP* site, the final product of the testes-specific self-excision reaction.

Figure 2 shows targeting of a self-excision cassette to *Hoxa3*. In Figure 2A is shown the self-excision cassette, ACN. Testes-specific elements from the mouse *ACE* gene (black arrow) are placed 5' of the modified *Cre* structural gene (Gu et al., 1992) (red), followed, 3', with the minimal polyadenylation signal from *HSV-TK* (Thomas et al., 1987) (white box). An intron, derived from the SC40 *t*-antigen gene (white box) is inserted into the *Cre* gene, the *Neo'* gene (blue) is controlled by a promoter from the mouse RNA polymerase II gene (black arrow) and followed also by the *HSV-TK* poly(A) site (white box). The 5' and 3' ends of this cassette contain *loxP* sites (P). Figure 2B shows gene targeting at *Hoxa3*. In the top line, the targeting vector pRVA3^{ACN} contains 11 kb of mouse genomic DNA into which the self-excision cassette ACN has been inserted in the homeodomain of *Hoxa3* (McGinnis et al., 1984), the genomic sequences are linked to the *HSV-TK* gene (dark gray) and are all contained on a pUC-based plasmid backbone (light gray). The ACN cassette contains at its 5' end an *SstI* site (S), used as a marker for homologous integration of the cassette at the *Hoxa3* gene. On the second line, the wild-type *Hoxa3* locus, and the bottom line, the predicted structure of the recombinant *Hoxa3*^{ACN} allele. The 5' flanking probe used to detect recombination is indicated, and the diagnostic *SstI*-generated DNA fragments delineated beneath each locus. Yellow boxes designate *Hoxa3* exons, other *SstI* sites in the vector are not indicated. In Figure 2C, in Southern transfer analysis, DNA from the parental cell line (ES) and the homologous recombinant ES lines used to generate mice was restricted with *SstI*. Radiolabelled DNA probe is depicted in b.

Figure 3 shows genetic transmission of *Hoxa3* alleles. In Figure 3A, the PCR-based genotyping of the three *Hoxa3* alleles shows primer 1 (p1) is from the *Hoxa3* intron, primer 2 (p2) is from coding exon 2-derived sequences (antisense), and primer 3 (p3) is from the *Neo'* gene. Predicted sites are indicated, color coding is as in Figure 2. Figure 3B shows genotyping of DNA from wild-type ES cells (ES), recombinant ES cell line, 1h-9, tail biopsies from a chimeric male, 3227, generated from 1h-9, and tail tissue from F₁ progeny of the chimera. Amplified DNA was electrophoresed through agarose and stained with ethidium bromide. Sizes correspond to those

listed in Figure 3A. Figure 3C shows the absence of excision in somatic tissue. A single chimeric male derived from cell line 1h-9 was sacrificed at eight weeks of age. DNA extracted from each of the indicated tissues was analyzed by PCR as in Figure 3B. Analysis of a second chimera showed an identical result.

DETAILED DESCRIPTION OF THE INVENTION

In accordance with a first aspect of the present invention, a method is provided for the self-excision of nucleic acid sequences in desired tissues of organisms, i.e., plants or animals. According to this aspect, a DNA molecule, as described herein, which has been designed to provide deletion of a foreign DNA in the desired tissue of an organism is introduced into an organism. The organism is grown resulting in the excision of the foreign DNA in the desired tissue. In one embodiment, the DNA molecule is introduced to produce a transgenic organism. Alternatively, the nucleic acid molecule could be introduced into an organism, such as in gene therapy. In one embodiment, the method provides for the self-excision of nucleic acid sequences in the germline. In this embodiment, the foreign DNA is excised in the transgenic organism during gametogenesis. In a second embodiment, the method provides for the self-excision of nucleic acid sequences in specific tissue. In this embodiment, the foreign DNA is excised in the specific somatic tissue during growth of the organism. The "foreign" DNA may be heterologous DNA, such as a marker sequence, or it may be a wild-type allele, such as for use in gene therapy, and its presence in the germline of the transgenic organism or in certain tissue of the organism is usually not desired. The DNA molecule may further contain a gene which is desired to be incorporated into the transgenic organism or into tissue in the organism. The method of the present invention prevents germline transmission of the foreign DNA or prevents somatic expression of the foreign DNA in non-desired tissue.

In accordance with a second aspect of the present invention, a DNA molecule is provided which is useful in the method of the present invention. The DNA molecule comprises (a) a recombinase site, (b) a tissue specific promoter, (c) a recombinase gene, (d) a foreign DNA and (e) a recombinase site. In one embodiment, the tissue specific promoter is a gamete-specific promoter. In a second embodiment, the tissue specific promoter is a somatic tissue-specific promoter. The DNA molecule may further comprise a gene which is desired to be incorporated into and expressed in an organism. The foreign DNA may be heterologous DNA, such as a marker sequence, or it may be a wild-type allele, such as for use in gene therapy, and its presence in the germline of the

transgenic organism is usually not desired. Examples of recombinase sites include, but are not limited to, *loxP* and *FRT*. Examples of recombinase genes include, but are not limited to, *Cre* and *FLP*. The foreign DNA survives preparing transgenic cells, selection of transgenic cells, and in somatic cells remains integrated but (a) in one embodiment is excised during gametogenesis as the transgenic organism grows or (b) in a second embodiment is excised in a tissue specific manner as the transgenic organism grows.

The present invention is further described with reference to a first embodiment in which nucleic acid sequences are deleted as they pass through the germline of plants or animals. It is understood that the method is also applicable to deletion of nucleic acid sequences in specific tissues of plants or animals through the use of a particular tissue specific promoter in place of the gamete-specific promoter discussed in this description.

A procedure is described that directs self-induced deletion of nucleic acid sequences as they pass through the germline of plants or animals. Although the method of the present invention is illustrated with reference to male germline of animals and using *Cre*, it is to be understood that the method is also applicable to female germline of animals, male germline of plants and female germline of plants and the use of other recombinase systems. As detailed herein, the testes-specific promoter from the angiotensin-converting enzyme gene is used to drive expression of the Cre-recombinase gene. *Cre* was linked to the selectable marker, *Neo^r*, and the two genes flanked with *loxP* elements. This cassette was targeted to the *Hoxa3* gene in mouse ES cells that were in turn used to generate chimeric mice. In these chimeras, somatic cells derived from the ES cells retained the cassette, but self-excision of the marker gene was found to have occurred in all ES-cell-derived sperm.

The strategy behind the present invention protocol is illustrated in Figure 1: the intragenic promoter of the murine angiotensin converting enzyme, *tACE* (shown to initiate transcription only during spermatogenesis), directs expression of Cre; *tACE-Cre* is linked to the selectable marker gene, *Neo^r*, and the two genes, *tACE-Cre/Neo^r*, are flanked with *loxP* sites. This cassette, referred to as ACN, is targeted by homologous recombination to a specific locus in a murine ES cell. Cells containing the appropriate chromosomal recombinant are inserted into a blastocyst-stage mouse embryo which develops into a chimeric animal, containing cells from both the host blastocyst and the cassette-containing ES cells. If the chimerism extends to the germline of an adult male, some fraction of the sperm will be ES-cell derived. During spermatogenesis the *tACE* promoter induces expression of the Cre-recombinase, the ACN cassette is excised, and a single *loxP* element remains

at the chromosomal locus. Progeny from these sperm should represent two classes of paternal transmission: (1) those containing a wild-type paternal chromosome, originating either from the non-targeted chromosome in the heterozygous ES cells or from non-ES (i.e. host)-derived cells; and (2) those containing a *loxP* insertion in the paternal chromosome.

The experimental design used to test this protocol is illustrated in Figure 2. Two features of the ACN-cassette should be noted: *Neo* is located 3' of the *tACE-Cre* gene, such that transcription of *Neo* should not result in transcriptional read-through of *Cre*; and the *Cre* gene contains an intron to prevent in-frame translation and subsequent self-excision in bacteria. We inserted the ACN cassette into a genomic clone of the mouse *Hoxa3* gene, and transfected the targeting vector into mouse ES cells. We clonally isolated 144 cell lines that survived positive-negative selection, and demonstrated by Southern transfer analysis that 20 contained the ACN-cassette integrated into one of the endogenous *Hoxa3* loci.

Three of the recombinant ES-cell lines were used to generate 13 male chimeric mice that in turn sired 138 ES-cell-derived progeny (determined by coat color). All progeny were genotyped by a PCR-based assay that could distinguish between the three potential *Hoxa3* alleles: wild type, ACN, and *loxP* (Fig. 3A) Figure 3B shows such an assay, comparing DNA isolated from the parental ES cell line, one recombinant ES cell line, tail biopsies from a chimeric male, and 6 of his agouti progeny. The recombinant ES cells and the chimera-derived tails are heterozygous for the wild-type and ACN-containing alleles whereas the F₁ progeny are either wild-type or heterozygous for the *loxP* allele. A summary of the genotypes of all 138 progeny, shown in Table 1, demonstrates that *tACE-Cre* mediated germline excision of the ACN cassette in all cases.

TABLE 1

Genotypic Analysis of Progeny

Cell Line	No. of Chimeras	Genotype of Progeny		
		<u>+/+</u>	<u>+/ACN</u>	<u>+/lox</u>
1d-7	3	23	0	26
1h-9	9	37	0	32
1f-9	1	7	0	13
Total	13	67	0	71

Male chimeric animals derived from 3 cell lines were mated with C57Bl/6 females. DNA was extracted from tails of all agouti pups and was genotyped as described herein. The number of animals with each genotype is indicated.

Although self-excision was complete at the level of spermatogenesis, it was also restricted to the testes. Tissues from chimeric males that transmitted the *loxP* allele were genotyped, and with the exception of the testes were heterozygous for the wild-type and the ACN alleles (Fig. 3C). Testes, which were mosaic for the two mutant *Hoxa3* alleles, include multiple cell types, only two of which, the elongating spermatids and the spermatozoa, should contain the *loxP* allele.

A similar protocol has been used to generate mice carrying a *loxP* insertion in the *Hoxd3* gene, which demonstrates the applicability of the present invention to a vast number of loci. The tACE promoter is inactive in somatic cells when integrated at independent ectopic sites. It also appears refractory to activation when integrated at random loci in ES cells, even when linked to a transcriptionally active *Neo^r* gene. Were the tACE promoter frequently expressed following integration in ES cells, the capacity of DNA carrying the self-excision cassette to generate stable transformants would be greatly reduced, but this is not the case. It remains possible, however, that if the cassette were targeted to a transcriptionally active locus, that the Cre protein could be translated from read-through mRNA transcribed into the cassette. Under such conditions, it would be necessary to custom-design a cassette containing transcription insulators or to place ACN in a transcriptional orientation opposite to that of the target locus.

The present method has many applications with plants and animals. One application is in the generation of knockout animals. The possibility that a marker gene may unpredictably affect phenotype has already prompted removal of such sequences prior to phenotypic analysis. Although alternative recombinase-based excision methods do exist, they are often accompanied with operational inconveniences. For example, removal of sequences during the growth of ES cells requires additional selection and/or screening. Not only is there a time and labor consideration involved in such manipulation, but the pluri-potency of ES cells can be adversely affected by prolonged growth in culture. Sequence deletion in the animal relies either on the expression of the recombinase in the fertilized eggs of animals carrying a *loxP*-flanked gene, the mating of such animals with a Cre-expressing mouse, or the use of ES cells containing a Cre-expressing transgene. All methods require additional breeding and/or technical expertise, and thus prolong by several months the time required for analysis.

The above pragmatic advantage will also be realized in the generation of chromosomal rearrangements typically mediated by Cre-catalyzed recombination or in the condensation of tandem repeats resulting from the random integration of transgenes following pronuclear injection. Linkage

of *tACE-Cre* to a *loxP* site defining the desired deletion endpoint should greatly simplify these chromosomal engineering processes.

A further application of the present invention is the generation of mice harboring conditional-mutant alleles. The creation of such animals often takes advantage of either the *Cre/loxP* or *FLP/FRT* recombination systems to create genetic deletions regulated by the restricted spatial or temporal expression of the appropriate recombinase. The recombinogenic elements, *loxP* or *FRT*, must first be introduced into the genome by linkage to a selectable marker gene. Because it is essential that the ground state of such experiments be wild-type, it is imperative that the marker gene not influence the expression of the target gene. If the two recombinase systems were employed in the same animal, for example, the self-excising cassette expressing FLP, and deletion elements responding to the conditional expression of *Cre*, such a requirement could be met.

Another application of the self-excision method of the present invention is in the area of agricultural crops. New strains of agricultural crops are now equipped with 'terminator' genes to limit the propagation of proprietary traits. A self-excision mechanism activated only in the germline would provide a single step method to restrict those traits to a single, founding generation, and may reduce the threat of unintended transmission of genetic traits to non-target species.

In addition, the present method can be used as part of *in utero* human gene therapy as a means to correct genetic deficiencies. Because such protocols will induce genetic changes in embryonic cells, including those that may colonize the germline, they have raised both moral and pragmatic objections. If, however, such modifications were linked with a germline-expressed recombinase and flanked with recombinogenic elements, the challenges to such modifications will be removed along with the intervening DNA.

The present method can also be used to delete undesired DNA, such as may be introduced in gene therapy, in a tissue in which expression is not desired.

EXAMPLES

The present invention is further detailed in the following Examples, which are offered by way of illustration and are not intended to limit the invention in any manner. Standard techniques well known in the art or the techniques specifically described below are utilized. GenBank accession numbers: SV40 t-antigen (J02400); *loxP* (M10287); RNA polymerase II large subunit (M14101); ACE (M61094); Neo (V00618).

EXAMPLE 1

Vector Construction

The self-excision cassette was assembled into the bacterial plasmid, pBS (Stratagene) using standard cloning methods. The *tACE* promoter sequences are nucleotides 495 to 1194; the *Cre* gene includes the entire protein-coding domain from pMC1-Cre followed by the minimal polyA sequence from the *HSV-TK* gene; intron sequences from the SV40 t-antigen gene, nucleotides 4637-4572, were amplified by PCR and inserted between codons 283 and 284 of *Cre*; the *Neo^r* gene is an 873-bp *Pst*I to *Bam*HI fragment isolated from pMC1Neo-polyA; the promoter includes bases 1 to 713 from the mouse RNA polymerase II large subunit gene; the 34-bp minimal *loxP* sites are in parallel orientation at each end of the cassette. Murine *Hoxa3* sequences were isolated from a λ phage library constructed in this laboratory of genomic DNA isolated from ES cells. Sequences used for the targeting vector extend from a *Sau*3A1 site, 2.2 kb upstream of the ATG in exon 1 to an *Eco*RI site 5.5 kb 3' of the TGA in exon 2. ACN was inserted into the *Bgl*II site in the homeodomain in exon2. An 8-bp *Exo*RV-containing oligonucleotide linker was also inserted at the *Eco*47III-site in exon 1. This introduces a premature stop codon, creating an allele of *Hoxa3* to be used in future studies of this locus.

EXAMPLE 2

ES cells: Transformation, Screening and Blastocyst Injection

The targeting vector, pRVa3^{ACN}, was introduced in linear form by electroporation into R1ES cells that were subsequently selected for resistance to G418 and FIAU. Approximately 2×10^7 cells were subjected to electroporation and 144 drug-resistant colonies isolated. DNA was extracted from cells of each clone and subjected to analysis by Southern transfer under previously described conditions. Homologous recombination was verified following digestion with two separate restriction endonucleases and hybridization with three individual probes. No rearrangements other than the predicted homologous recombination reaction were seen, nor were any homologous recombination events accompanied by detectable random integration of vector sequences. Cells from clones identified as heterozygous at the *Hoxa3* locus were injected into C57Bl/6-derived blastocysts that were allowed to come to term. Chimeric progeny were identified by coat color and those males estimated to contain >80% ES cell contribution were mated with C57Bl/6 females.

EXAMPLE 3

Tissue and cell genotype analysis

DNA was extracted from tail biopsies of chimeric males and their progeny, as well as from tissues isolated from euthanized chimeric animals, and resuspended in TE buffer. Approximately 1 μ g of DNA was dissolved in 40 μ l of a PCR lysis buffer, denatured at 95°C for five minutes, and quick-chilled on ice. Five microliters of the denature DNA solution was amplified for 30 cycles in a 25- μ l reaction mixture under previously described reaction conditions and cycling parameters. Primer sequences were as follows: Primer 1: 5'-GCTCTTCTCTCTGIGTCTG-3' (SEQ ID NO:1), represents sequences 5' of the splice acceptor site in the *Hoxa3* intron; Primer 2: 5'-CGAATGCATAGAATTCAGATAGCC-3' (SEQ ID NO:2), is antisense sequence from *Hoxa3*, nucleotides 849 to 826; primer 3: 5'-GCCTGCTTGCCGATTATCATGG-3' (SEQ ID NO:3), is from the sense strand of the *Neo^r* gene, nucleotides 2121 to 2142. Amplified products were analyzed by electrophoresis through 3% NuSieve 3:1 agarose (FMC). Figure 3B shows products from single, 25 μ l reactions; Figure 3C contains pools of eight amplification reactions.

While the invention has been disclosed in this patent application by reference to the details of preferred embodiments of the invention, it is to be understood that the disclosure is intended in an illustrative rather than in a limiting sense, as it is contemplated that modifications will readily occur to those skilled in the art, within the spirit of the invention and the scope of the appended claims.

LIST OF REFERENCES

- Araki, K. M., et al. (1995). Site-specific recombination of a transgene in fertilized eggs by transient expression of Cre-recombinase. *Proc. Natl. Acad. Sci. USA* **92**:160-164.
- Broach, J.R., et al. (1980). Replication and recombination functions associated with the yeast plasmid, 2m circle. *Cell* **21**:501-508.
- Capecechi, M.R. (1999). Human germline gene therapy: a discussion on how and why. In: *Engineering the Human Germline* (ed. G. Stock, J. Campbell), Oxford Univ. Press, New York, NY.
- Colledge, W.H., et al. (1995). Generation and characterization of a DF508 cystic fibrosis mouse model, *Nature Genet.* **10**:445-452.
- Deng, C., et al. (1993). Location of crossovers during gene targeting with insertion and replacement vectors, *Mol. Cell. Biol.* **13**:2134-2140.
- Ewbank, J. (1998). Problems of germline therapy, *Nature* **392**: 645.

- Garrick, D., et al. (1998). Repeat-induced gene silencing in mammals, *Nature Genet.* **18**: 56-59.
- Gu, H., et al. (1994). Deletion of a DNA polymerase beta gene segment in T cells using cell type-specific gene targeting, *Science* **265**:103-106.
- Gu, H., et al. (1993). Independent control of immunoglobulin switch recombination at individual switch regions evidenced through Cre-loxP-mediated gene targeting, *Cell* **73**:1155-1164.
- Hasty, P., et al. (1991). Introduction of a subtle mutation into the Hox-2.6 locus in embryonic stem cells, *Nature* **350**:243-246.
- Hérault, Y., et al. (1998). Engineering chromosomes in mice through targeted meiotic recombination (TAMERE), *Nature Genet.* **20**:381-384.
- Langford, K.G., et al. (1991). Transgenic mice demonstrate a testis-specific promoter for angiotensin-converting enzyme, *J. Biol. Chem.* **266**:15559-15562.
- McGinnis, W., et al. (1984). Molecular cloning and chromosome mapping of a mouse DNA sequence homologous to homeotic genes of *Drosophila*, *Cell* **38**:675-680.
- McLaren, A. (1998). Problems of germline therapy, *Nature* **392**: 645.
- Meyers, E.N., et al. (1998). An Fgf8 mutant allelic series generated by Cre- and Flp-mediated recombination, *Nature Genet.* **18**:136-141.
- Nagy, A., et al. (1993). Derivation of completely cell culture-derived mice from early-passage embryonic stem cells, *Proc. Natl. Acad. Sci. USA* **90**:8424-8428.
- O'Gorman, S., et al. (1997). Protamine-Cre recombinase transgenes efficiently recombine target sequences in the male germ line of mice, but not in embryonic stem cells, *Proc. Natl. Acad. Sci. USA* **94**:14602-14607.
- Olson, E.N., et al. (1996). Know your neighbors: Three phenotypes in null mutants of the myogenic bHLH gene MRF4, *Cell* **85**:1-4.
- Pikaart, M.J., et al. (1998). Loss of transcriptional activity of a transgene is accompanied by DNA methylation and histone deacetylation and is prevented by insulators, *Genes Dev.* **12**:2852-2862.
- Ramírez-Solis, R., et al. (1995). Chromosome engineering in mice, *Nature* **378**:720-724.
- Rossant, J., et al. (1999). "Cre"-ating mouse mutants--a meeting review on conditional mouse genetics, *Genes Dev.* **13**:142-145.
- Schwenk, F., et al. (1995). A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. *Nucleic Acids Res.* **23**:5080-5081.
- Service, R.F. (1998). Seed-sterilizing 'terminator technology' sows discord, *Science* **282**:850-851.
- Smith, A.J.H., et al. (1995). A site-directed chromosomal translocation induced in embryonic stem cells by Cre-loxP recombination, *Nature Genet.* **9**:376-385.
- Spyropoulos, D.D., et al. (1994). Targeted disruption of the even-skipped gene, *evx1*, causes early postimplantation lethality of the mouse conceptus, *Genes Dev.* **8**:1949-1961.
- Sternberg, N., et al. (1981). Bacteriophage P1 site-specific recombination. I. Recombination between loxP sites, *J. Mol. Biol.* **150**:467-486.

Thomas, K.R., et al. (1987). Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells, *Cell* **51**:503-512.

Wadman, M. (1998). US gene-therapy proposals come under fire, *Nature* **395**:309.

0450522.06200

WHAT IS CLAIMED IS:

1. A method for deleting a nucleic acid sequence in a specified tissue of an organism from a DNA molecule introduced into the organism which comprises:

(a) introducing a DNA molecule into an organism, said DNA molecule comprises
5 a recombinase site, a tissue-specific promoter, a recombinase gene, a foreign DNA and a recombinase site; and

(b) growing said organism such that the tissue-specific promoter is active for expression of said recombinase gene in the specified tissue,

whereby said foreign DNA is deleted in the specified tissue during growth of the organism.

2. The method of claim 1, wherein the DNA molecule further comprises a gene which is desired to be expressed in the organism.

3. The method of claim 1, wherein said foreign DNA is heterologous DNA.

4. The method of claim 2, wherein said foreign DNA is heterologous DNA.

5. The method of claim 1, wherein said foreign DNA is a wild-type allele or fragment thereof of a gene for use in gene therapy.

6. The method of claim 2, wherein said foreign DNA is a wild-type allele or fragment thereof of a gene for use in gene therapy.

7. The method of claim 1, wherein the promoter is specific to the male or female gamete.

8. The method of claim 7, wherein the DNA molecule further comprises a gene which is desired to be expressed in the organism.

9. The method of claim 7, wherein said foreign DNA is heterologous DNA.

10. The method of claim 7, wherein said foreign DNA is a wild-type allele or fragment thereof of a gene for use in gene therapy.

11. The method of claim 7, wherein the introduction of the DNA molecule into an organism produces a transgenic organism and the foreign DNA is deleted during gametogenesis in the transgenic organism.

12. The method of claim 11, wherein said foreign DNA is heterologous DNA.

13. The method of claim 11, wherein said foreign DNA is a wild-type allele or fragment thereof of a gene for use in gene therapy.

14. The method of claim 8, wherein the introduction of the DNA molecule into an organism produces a transgenic organism and the foreign DNA is deleted during gametogenesis in the transgenic organism.

15. The method of claim 14, wherein said foreign DNA is heterologous DNA.

16. The method of claim 14, wherein said foreign DNA is a wild-type allele or fragment thereof of a gene for use in gene therapy.

17. The method of claim 1, wherein said organism is an animal.

18. The method of claim 1, wherein said organism is a plant.

19. The method of claim 17, wherein the animal is a knockout animal.

20. A nucleic acid molecule comprising (a) a recombinase site, (b) a tissue-specific promoter, (c) a recombinase coding sequence, (d) a foreign DNA and (e) a recombinase site.

21. The molecule of claim 20, wherein said recombinase site is selected from the group consisting of *loxP* and *FRT*.

22. The molecule of claim 20, wherein said recombinase gene is selected from the group consisting of *Cre* and *FLP*.
23. The molecule of claim 21, wherein said recombinase gene is selected from the group consisting of *Cre* and *FLP*.
- 5 24. The method of claim 20, wherein said molecule further comprises a gene which is desired to be expressed in an organism.
25. The molecule of claim 20, wherein the promoter is specific to the male or female gamete.
26. The molecule of claim 23, wherein the promoter is specific to the male or female gamete.
27. The method of claim 25, wherein said molecule further comprises a gene which is desired to be expressed in an organism.
- 10 28. The method of claim 26, wherein said molecule further comprises a gene which is desired to be expressed in an organism.
29. The method of claim 20, wherein said foreign DNA is heterologous DNA.
30. The method of claim 25, wherein said foreign DNA is heterologous DNA.
- 15 31. The method of claim 26, wherein said foreign DNA is heterologous DNA.
32. The method of claim 20, wherein said foreign DNA is a wild-type allele or fragment thereof of a gene for use in gene therapy.
33. The method of claim 25, wherein said foreign DNA is a wild-type allele or fragment thereof of a gene for use in gene therapy.

34. The method of claim 26, wherein said foreign DNA is a wild-type allele or fragment thereof of a gene for use in gene therapy.
35. A non-human transgenic organism comprising the nucleic acid molecule of claim 20.
36. The non-human transgenic organism of claim 35, wherein said organism is a plant.
37. The non-human transgenic organism of claim 35, wherein said organism is an animal.

5

200309.22299950

TITLE OF THE INVENTION

SELF-INDUCED DELETION OF DNA

ABSTRACT OF THE DISCLOSURE

5 The present invention is directed to a method for deleting DNA sequences in a tissue specific manner. In one embodiment, DNA sequences are specifically deleted in germline tissue. In a second embodiment, DNA sequences are specifically deleted in desired somatic tissue. The present invention is further directed to a nucleic acid molecule for use in the method. More specifically, a nucleic acid molecule is provide by the present invention which comprises (a) a recombinase site, (b) a tissue-specific promoter, (c) a recombinase gene, (d) a foreign DNA, and (e) a recombinase site. The nucleic acid molecule may further comprise a gene which is desired to be incorporated into and expressed in a transgenic organism. The method can be used in both plants and animals, and has many applications as described herein.

00000000000000000000




FIG. 2A




FIG. 2B






FIG. 2C



006290-22290960

FIG. 3A



006290-22290640

FIG.3B





FIG.3C



22

[illegible]